You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

AstraZeneca’s Eplontersen meets endpoints in critical phase 3 trial

Positive results from the NEURO-TTRansform phase 3 trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met all its co-primary endpoints.